Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-01-17
2006-01-17
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S142100, C424S145100, C424S134100, C530S387100, C530S387300, C530S388150, C530S388240
Reexamination Certificate
active
06986889
ABSTRACT:
The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.The invention provides a Fab (antibody fragment), having the following characteristics:a) inhibits the IgE-FcεRI interaction;b) binds to free and cell-bound IgE; andc) is non-anaphylactic.
REFERENCES:
patent: 5543144 (1996-08-01), Chang
patent: 5625039 (1997-04-01), Washida et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 00 63252 (2000-10-01), None
patent: 00 72879 (2000-12-01), None
Colman et al, 1994, A structural view of immune recognition by antibodies, pp. 33-34.
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.
Heusser et al, Current Opinion in Immunology 9: 805-814, 1997.
Harlow et al in Antibodies a Laboratory Manual, 1998, Cold Spring harbor laboratory publication, Cold Spring Harobr, NY, pp. 626-629.
Rudolf et al, J Immunology 157: 5646-5652, 1996.
Valenta et al, International archives of allergy and immunology 113(1-3): 258-9, 1997.
Kuby et al, 1994, Immunology, Second edition, pp. 86-96.
V. Casolaro et al., “Biology and Genetics of Atopic Disease”,Curr. Opin. Immunol., 1996, pp. 796-803, vol. 8.
M.A. Beaven et al., “Signal Transduction by Fc Receptors: The FcεRI Case”,Immunology Today, 1993, pp. 222-226, vol. 14, No. 5.
G.C. Mudde et al., “Allergen Presentation by Epidermal Langerhans' Cells from Patients with Atopic Dermatitis is Mediated by IgE”,Immunology, 1990; pp. 335-341, vol. 69.
D. Maurer et al., “The High Affinity IgE Receptor (FcεRI) Mediates IgE-Dependent Allergen Presentation”,Journal of Immunology, 1995, pp. 6285-6290, vol. 154.
T. Bierber, “ FcεRI ON antigen-pRESenting Cells”,Curr. Opin. Immunol., 1996, pp. 773-777, vol. 8 .
K. Ishizaka et al., “Identification of äE-Antibodies as a Carrier of Reaginic Activity”,The Journal of Immunology, 1967, pp. 1187-1198, vol. 99, No. 6.
S.G.O. Johansson et al., “Immunological Studies of an Atypical (Myeloma) Immunoglobulin”,Immunology, 1967, pp. 381-394, vol. 13.
J.V. Ravetch et al., “Fc Receptors”,Ann. Rev. Immunol., 1991, pp. 457-492, vol. 9.
B. Helm et al., “Peptide Blocking of IgE/Receptor Interaction: Possibilities and Pitfalls”,Allergy, 1997, pp. 1155-1169, vol. 52.
B. Helm et al., “The Mast Cell Binding Site on Human Immunoglobulin E”,Nature, Jan. 1988, pp. 180-183, vol. 331, No. 14.
B. Helm et al., “Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E”,The Journal of Biological Chemistry, 1996, pp. 7494-7500, vol. 271.
A. Nissim et al., “Mapping of the High Affinity Fcå Receptor Binding Site to the Third Constant Region Domain of IgE”,The EMBO Journal, 1991, pp. 101-107, vol. 10, No. 1.
L. Presta et al., “The Binding Site on Human Immunoglobin E for Its High Affinity Receptor”,The Journal of Biological Chemistry, 1994, pp. 26368-26373, vol. 269, No. 42.
B. Helm et al., “Blocking of Passive Sensitization of Human Mast Cells and Basophil Granulocytes with IgE Antibodies by a Recombinant Human å-chain Fragment of 76 Amino Acids”,Proc. Natl. Acad. Sci., 1989, pp. 9465-9469, vol. 86.
M. Basu et al., “Purification and Characterization of Human Recombinant IgE-Fc Fragments that Bind to the Human High Affinity IgE Receptor”,The Journal of Biological Chemistry, 1993, pp. 13118-13127, vol. 268, No. 18.
L. Vangelista et al., “The Immunoglobulin-like Modules Cå3 and å2 are the Minimal Units Necessary for Human IgE-FcåRI Interaction”,The Journal of Clinical Investigation, 1999, pp. 1571-1578, vol. 103, No. 11.
R.N. Hamburger, “Peptide Inhibition of the Prausnitz-Küstner Reaction”,Science, 1975, pp. 389-390, vol. 189.
J.M. McDonnell et al., “Structure Based Design and Characterization of Peptides that Inhibit IgE Binding to Its High-Affinity Receptor”,Nature Structural Biology, 1996, pp. 419-426, vol. 3, No. 5.
S.C. Garman et al., “Crystal Structure of the Human High-Affinity IgE Receptor”,Cell, pp. 951-961, vol. 96.
L. Hellman, “Profound Reduction in Allergen Sensitivity Following Treatment With a Novel Allergy Vaccine”,Eur. J. Immunol., 1994, pp. 415-420, vol. 24.
T.W. Wiegand et al., “High-Affinity Oligonucleotide Ligands to Human IgE Inhibit Binding to Fcå Receptor I”,J. Immunol., 1996, pp. 221-230, vol. 157.
L.G. Presta et al., “Humanization of an Antibody Directed Against IgE”,The Journal of Immunology, 1993, pp. 2623-2632, vol. 151, No. 5.
C. Heusser et al., “Therapeutic Potential of Anti-IgE Antibodies”,Curr. Opin. Immunol., 1997, pp. 805-813, vol. 9.
S.T. Holgate et al., “Treatment of Allergic Airways Disease with Anti-IgE”,Allergy, 1998, pp. 83-88, vol. 53.
D.T.W. Fei et al., “A Novel Bioactivity Assay for Monoclonal Antibodies Directed Against IgE”,Journal of Immunological Methods, 1994, pp. 189-199, vol. 171.
C.H. Heusser et al., “Demonstration of the Therapeutic Potential of Non-Anaphylactogenic Anti-IgE Antibodies in Murine Models of Skin Reaction, Lung Function and Inflammation”,Int. Arch. Allergy Immunol., 1997, pp. 231-235, vol. 113.
H. Breiteneder et al., “The Gene Coding for the Major Birch Pollen Allergen Betvi, is Highly Homologous to a Pea Disease Resistance Response Gene”,The EMBO Jounral, 1989, pp. 1935-1938, vol. 8, No. 7.
S. Laffer et al., “Molecular Characterization of Bip 1, a Monoclonal Antibody that modulates IgE Binding to Birch Pollen Allergen, Bet v 11”,J. Immunol., 1996, pp. 4953-4962, vol. 157.
K. Hoffman-Sommergruber et al., “High-Level Expression and Purification of the Major Birch Pollen Allergen, Bet v 1”,Protein Expression and Purification, 1997, pp. 33-39, vol. 9.
P. Wiedemann et al., “Molecular and Structural Analysis of a Continuous Birch Profilin Epitope Defined by a Monoclonal Antibody”,The Jounral of Biological Chemistry, 1996, pp. 29915-29921, vol. 271, No. 47.
K.H. Roux, “Immunoelectron Microscopy of Idiotype-Anti-Idiotype Complexes”,Meth. Enzymol, 1989, pp. 130-144, vol. 178.
K.H. Roux, “Negative-Stain Immunoelectron-Microscope Analysis of Small Macromolecules of Immunologic Significance”,Methods: A Companion to Methods in Enzymology, 1996, pp 247-256, vol. 10.
K.H. Roux et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry”,J. Immunol., 1998, pp. 4083-4090, vol. 161.
P. Valent et al., “Mast Cell Typing: Demonstration of a Distinct Hematopoietic Cell Type and Evidence for Immunophenotypic Relationship to Mononuclear Phagocytes”,Blood, 1989, pp. 1778-1785, vol. 73.
A.L. De Weck et al., “Good or Bad IgE and Anti-IgE Antibodies: New Molecular Concepts”,Molecular Biology and Immunology of Allergens, Boca Raton, Florida: CRC Press, 1993, pp. 101-112.
M.P Rudolf et al., “Effect of Anti-IgE Antibodies on FcεRI-Bound IgE1”,J. Immunol., 1996, pp. 5646-5652, vol. 157.
M.B. Keown et al., “Hydrodynamic Studies of a Complex Between the Fc Fragment of Human IgE and a Soluble Fragment of the FcεRI α Chain”,Proc. Natl. Acad. Sci., 1995, pp. 1841-1845, vol. 92.
M.B. Keown et al., “Basis of the 1:1 Stoichiometry of the High Affinity Receptor Fcε RI-IgE Complex”,Eur. Biophys. J., 1997, pp. 471-476, vol. 25.
P. Valent et al., “Interleukin 3 Activates Human Blood Basophils Via High-Affinity Binding Sites”,Proc. Natl. Acad. Sci., 1989, pp. 5542-5546, vol. 86.
R. Valenta et al., “Induction of Specific Histamine Release from Basophils with Purified Natural and Recombinant Birch Pollen Allergens”,J. Allergy Clin. Immunol., 1993, pp. 88-97, vol. 91.
H.
Adriansson Jonas
Grönlund Hans
Högbom Erik
Kraft Dietrich
Laffer Sylvia
Browdy and Neimark
Chan Christina
Huynh Phuong
Pharmacia Diagnostics AB
LandOfFree
Compound for treatment of allergy and asthma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound for treatment of allergy and asthma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound for treatment of allergy and asthma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532546